Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CEP-37250/KHK2804 · 1 trial · 3 indications
The safety of CEP-37250/KHK2804 will be determined by reported adverse events (AEs), changes in the physical examinations, vital laboratory evaluations, and treatment discontinuations due to toxicity.
| Arm | Type | Description |
|---|---|---|
| Part 1 | EXPERIMENTAL | Dose escalation in subjects with advanced solid tumors with Part 1 which includes intervention of CEP-37250/KHK2804 |
| Part 2 | EXPERIMENTAL | Subjects with colorectal or pancreatic cancer Part 2 which includes intervention of CEP-37250/KHK2804 |
| Name | Type | Description |
|---|---|---|
| CEP-37250/KHK2804 | DRUG | Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804. Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1. |
Inclusion Criteria: * Adequate hepatic, renal, and hematologic function; * Life expectancy \> 3 months; * Part 1 and 2: The subject has histopathologically or cytologically documented, measurable, unresectable, locally advanced primary or recurrent, metastatic solid tumor, locally advanced primary ...
CEP-37250/KHK2804 is an investigational small molecule being developed for the treatment of solid tumors, including adenocarcinoma of the colorectal and adenocarcinoma of the pancreas. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
CEP-37250/KHK2804 is a small molecule, but its specific molecular target has not been disclosed. The drug is being studied in oncology for the treatment of advanced solid tumors, including colorectal and pancreatic adenocarcinomas.
CEP-37250/KHK2804 is being developed by Teva Pharmaceutical Industries Limited, a company listed on the stock exchange under the ticker TEVA. The drug is currently in Phase 1 clinical development for solid tumors.
CEP-37250/KHK2804 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. A Phase 1 study has been completed, but the drug remains in early-stage clinical testing.
CEP-37250/KHK2804 has been studied in one clinical trial, NCT01447732, titled 'Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors.' This trial enrolled 71 participants with solid tumors, colorectal adenocarcinoma, and pancreatic adenocarcinoma, and has been completed.
Yes, CEP-37250/KHK2804 is also known as KHK2804. The drug is referred to by both names in clinical research, and the Phase 1 trial NCT01447732 uses the combined name CEP-37250/KHK2804 to identify the investigational agent.